| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 08/18/2009 | US7576184 Monoclonal antibody for use in detection of plant protein associated with natural rubber; diagnosing latex allergies and hypersensitivity |
| 08/18/2009 | US7576178 DADD, death activator death domain protein |
| 08/18/2009 | US7576117 Cyclic amine CCR3 antagonist |
| 08/18/2009 | US7576104 4-(Aminomethyl)-2-(2,6-dioxo(3-piperidyl))isoindoline-1,3-dione hydrochloride; cytokines level reduced; tumor necrosis factor inhibitors; nontoxic; anticarcinogenic agents; antitumor agents (solid/blood-borne); cardiovascular disorders; osteoporosis; antiinflammatory agents; autoimmune diseases |
| 08/18/2009 | US7576079 Viral polymerase inhibitors |
| 08/18/2009 | US7576070 for inhibiting galectin-3- mediated cell-cell and/or cell-matrix Interactions leading to tumor diseases; hydrolyzing enzyme A |
| 08/18/2009 | US7575923 CD19xCD3 specific polypeptides and uses thereof |
| 08/18/2009 | US7575742 Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist |
| 08/18/2009 | CA2400268C Pyrrolopyrimidinone derivatives, process of preparation and use |
| 08/18/2009 | CA2377254C Non-malignant disease treatment with ras antagonists |
| 08/18/2009 | CA2335250C Temperature-sensitive liposomal formulation |
| 08/18/2009 | CA2288215C Use of immunomodulating agents |
| 08/18/2009 | CA2174526C Pseudodipeptide product possessing an imidazole group and the therapeutic, cosmetological and agri-food applications of the said product |
| 08/18/2009 | CA2105552C Soluble ligands for cd40 |
| 08/13/2009 | WO2009100324A1 Engineered anti-tslpr antibodies |
| 08/13/2009 | WO2009100194A2 Camptothecin-binding moiety conjugates |
| 08/13/2009 | WO2009100171A1 Fused heteroaryl modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof |
| 08/13/2009 | WO2009100170A1 Dual pharmacophores - pde4-muscarinic antagonistics |
| 08/13/2009 | WO2009099672A2 Breaking immunological tolerance with a genetically encoded unnatural amino acid |
| 08/13/2009 | WO2009099147A1 Il-1 type ii receptor gene-deficient mutant of mouse |
| 08/13/2009 | WO2009098649A1 Immunosuppressive macrolide powder for oral suspension |
| 08/13/2009 | WO2009098592A2 Preparation comprising mycobacterium bovis bcg killed by extended freeze drying (efd) for preventing or treating rheumatoid arthritis. |
| 08/13/2009 | WO2009098454A2 Treatment of diseases and conditions mediated by eicosanoids |
| 08/13/2009 | WO2009098344A1 Compositions and methods for modulating p300 activity |
| 08/13/2009 | WO2009098320A2 Macrolides for treating diseases mediated through pde inhibition |
| 08/13/2009 | WO2009060281A3 Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties |
| 08/13/2009 | WO2009043525A3 Use of the combination of gluten exorphin c and cd36 as a therapeutic agent |
| 08/13/2009 | WO2009043477A3 Use of glpl (7-36) alone or in combination with leptin 22-56 as a therapeutic agent |
| 08/13/2009 | WO2009043453A3 Use of a peptide as a therapeutic agent |
| 08/13/2009 | WO2009043436A3 Use of af12198 as a therapeutic agent |
| 08/13/2009 | WO2009040031A3 Use of a peptide as a therapeutic agent |
| 08/13/2009 | WO2009039991A3 Use of aviptadil as a therapeutic agent |
| 08/13/2009 | WO2009039964A3 Use of glucagon-like peptide as a therapeutic agent |
| 08/13/2009 | WO2009033792A3 Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent |
| 08/13/2009 | WO2009033770A3 Calcitonin c-terminal flanking peptide for use as a therapeutic agent |
| 08/13/2009 | US20090203878 Tryptophan as a functional replacement for adp-ribose-arginine in recombinant proteins |
| 08/13/2009 | US20090203798 Solid Pharmaceutical Compositions Comprising a SIP Receptor Agonist and a Sugar Alcohol |
| 08/13/2009 | US20090203782 Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders |
| 08/13/2009 | US20090203767 Inhibition stat-1 |
| 08/13/2009 | US20090203760 CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS |
| 08/13/2009 | US20090203757 Ethylene glycol esters as photoactive agents |
| 08/13/2009 | US20090203752 Compounds for nonsense suppression, and methods for their use |
| 08/13/2009 | US20090203739 Anti-Inflammatory Agents |
| 08/13/2009 | US20090203734 F1f0-atpase inhibitors and related methods |
| 08/13/2009 | US20090203711 Inhibitors of P38 Map Kinase |
| 08/13/2009 | US20090203702 INHIBITORS OF p38 |
| 08/13/2009 | US20090203698 Compounds for Enzyme Inhibition |
| 08/13/2009 | US20090203695 Compounds IV |
| 08/13/2009 | US20090203691 such as N1-{3-[3,5-Di(trifluoromethyl)phenyl]-1H-5-indazolyl}-(2R)-2-amino-3,3-diphenylpropanamide, having an excellent Jun N-terminal Kinase (JNK) inhibitory action, used for treating various immunologic diseases, inflammatory diseases, and/or neurodegenerative diseases |
| 08/13/2009 | US20090203668 Triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| 08/13/2009 | US20090203580 Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity |
| 08/13/2009 | US20090203114 Novel methods and interferon deficient substrates for the propagation of viruses |
| 08/13/2009 | US20090203036 Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto |
| 08/13/2009 | US20090202638 Bmp gene and fusion protein |
| 08/13/2009 | US20090202601 Method for inhibiting onset of or treating pollen allergy |
| 08/13/2009 | US20090202595 Anti-pdef antibodies and uses thereof |
| 08/13/2009 | US20090202593 Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
| 08/13/2009 | US20090202591 Leucine-based motif and clostridial neurotoxins |
| 08/13/2009 | US20090202588 Nucleic acids encoding TGEV and PRRSV sequences for improved expression of PRRSV sequences |
| 08/13/2009 | US20090202577 CASB618 Polynucleotides and Polypeptides and Their Use |
| 08/13/2009 | US20090202575 Immunostimulatory nucleic acid molecules |
| 08/13/2009 | US20090202574 Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer |
| 08/13/2009 | US20090202551 Immunomodulation by altering sphingosine 1-phosphate lyase (spl) activity |
| 08/13/2009 | US20090202541 Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl)-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
| 08/13/2009 | US20090202506 loading antigen presenting cells from a subject; loading antigen presenting cells (APC's) having Class I MHC (major histocompatibility factor) molecules with T cell epitopes; culturing CD8+ T cells with APC's; expanding in culture; for allergic asthma |
| 08/13/2009 | US20090202496 Method for regenerating an immune system |
| 08/13/2009 | US20090202487 Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology |
| 08/13/2009 | US20090202473 Combination of an anti-edb fibronectin antibody-il-2 fusion protein, and a molecule binding to b cells, b cell progenitors and/or their cancerous counterpart |
| 08/13/2009 | US20090202438 Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto |
| 08/13/2009 | DE102008007198A1 Oral oder nasal applizierbare Epinephrin- haltige Zubereitungen mit verbesserten Eigenschaften Orally or nasally administered epinephrine-containing formulations with improved properties |
| 08/13/2009 | CA2714389A1 Macrolides and uses of macrolides |
| 08/13/2009 | CA2714237A1 Immunosuppressive macrolide powder for oral suspension |
| 08/13/2009 | CA2713935A1 Engineered anti-tslpr antibodies |
| 08/13/2009 | CA2713933A1 Camptothecin-binding moiety conjugates |
| 08/13/2009 | CA2713032A1 Treatment of diseases and conditions mediated by eicosanoids |
| 08/13/2009 | CA2712080A1 Breaking immunological tolerance with a genetically encoded unnatural amino acid |
| 08/12/2009 | EP2088159A1 Antibody recognizing c-domain of midkine |
| 08/12/2009 | EP2087908A1 Antibodies to opgl |
| 08/12/2009 | EP2087907A2 Method and system to remove cytokine inhibitor in patients |
| 08/12/2009 | EP2087898A1 A preparation of mycobacterium bovis BCG killed by extended freeze drying (EFD) for treating rheumatoid arthritis |
| 08/12/2009 | EP2087897A1 Method for producing apyrogenic immunomodulator |
| 08/12/2009 | EP2087891A2 Pharmaceutical compositions for treating lymphoma |
| 08/12/2009 | EP2087886A1 Therapeutic agent for rheumatoid arthritis |
| 08/12/2009 | EP2087103A1 Cancerous disease modifying antibodies |
| 08/12/2009 | EP2087005A2 Compounds |
| 08/12/2009 | EP2086569A2 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases |
| 08/12/2009 | EP2086563A1 Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria |
| 08/12/2009 | EP2086553A1 Inhibition of degradation of extracellular matrix |
| 08/12/2009 | EP2086514A2 Pharmaceutical compositions comprising an s1p modulator |
| 08/12/2009 | EP1831209B1 Cdc25 phosphatase inhibitors |
| 08/12/2009 | EP1682121B1 Use of crth2 antagonist compounds in therapy |
| 08/12/2009 | EP1576011B1 Inhibition of il-17 production |
| 08/12/2009 | EP1567150B1 Derivatives of indole-3-carboxamide, preparation method thereof and application of same in therapeutics |
| 08/12/2009 | EP1409645B1 Probiotic lactobacillus salivarius strains |
| 08/12/2009 | EP1385882B9 Peptides and related molecules that bind to tall-1 |
| 08/12/2009 | EP1149111B1 Method and composition for angiogenesis inhibition |
| 08/12/2009 | EP1123711B9 Attenuated toxins as adjuvants |
| 08/12/2009 | EP0788360B3 Boronic ester and acid compounds, synthesis and uses |
| 08/12/2009 | CN101506239A Antihuman alpha9 integrin antibody and use of the same |
| 08/12/2009 | CN101506237A Anti-C5aR antibodies with improved properties |